Elevance Health, Inc. $ELV Stock Holdings Decreased by Camden National Bank

Camden National Bank lowered its position in shares of Elevance Health, Inc. (NYSE:ELV) by 21.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,106 shares of the company’s stock after selling 2,715 shares during the quarter. Camden National Bank’s holdings in Elevance Health were worth $3,265,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Elevance Health by 3.2% in the second quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company’s stock valued at $8,890,419,000 after purchasing an additional 704,790 shares in the last quarter. Sanders Capital LLC raised its position in Elevance Health by 24.7% during the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock valued at $2,265,773,000 after buying an additional 1,152,440 shares during the period. Artisan Partners Limited Partnership lifted its stake in Elevance Health by 9.7% in the 2nd quarter. Artisan Partners Limited Partnership now owns 3,675,179 shares of the company’s stock worth $1,429,498,000 after acquiring an additional 324,399 shares in the last quarter. Norges Bank purchased a new stake in Elevance Health in the 2nd quarter worth about $1,148,379,000. Finally, Massachusetts Financial Services Co. MA boosted its position in Elevance Health by 4.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,440,630 shares of the company’s stock worth $788,616,000 after acquiring an additional 112,020 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on ELV shares. Morgan Stanley reduced their price target on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 17th. Wolfe Research set a $425.00 target price on shares of Elevance Health and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Barclays decreased their target price on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Robert W. Baird upped their price target on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $332.00 price objective on shares of Elevance Health in a research report on Thursday, January 29th. Twelve research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Elevance Health presently has a consensus rating of “Moderate Buy” and an average target price of $390.55.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS forecast to $4.75 (from $3.48), a sign that Zacks expects stronger late‑year profitability which could support the stock if sustained. Elevance Health (ELV) on MarketBeat
• Neutral Sentiment: MSN ran a stock‑perspective piece highlighting two reasons to like ELV and one caveat; the article reinforces bullish arguments around Elevance’s scale and business stability but also flags at least one risk investors should weigh. 2 reasons to like ELV (and 1 not so much)
• Negative Sentiment: Zacks issued multiple cuts to near‑term and full‑year estimates — lowering FY2026 (to $25.53 from $29.01), FY2027 (to $28.40 from $31.89) and trimming several Q1/Q2 2026–2027 quarterly forecasts — which signals weaker expected growth in the coming quarters and is a potential headwind for the stock. Zacks Research Lowers Earnings Estimates for Elevance Health

Elevance Health Trading Up 3.1%

Elevance Health stock opened at $346.49 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56. The company has a market capitalization of $76.47 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 1.87 and a beta of 0.50. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75. The company’s fifty day moving average price is $352.22 and its two-hundred day moving average price is $331.73.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be given a $1.72 dividend. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s dividend payout ratio (DPR) is 27.23%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.